XML 59 R40.htm IDEA: XBRL DOCUMENT v3.26.1
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2025
Disclosure of supplementary financial statement information [Abstract]  
Schedule of Other Receivables
   
December 31,
 
   
2024
   
2025
 
   
in USD thousands
 
Government institutions
   
455
     
33
 

Advance payments

    91       -  
Other
   
932
     
377
 
     
1,478
     
410
 
Schedule of Accounts Payable and Accruals
   
December 31,
 
   
2024
   
2025
 
   
in USD thousands
 
1)          Trade:
           
        Accounts payable:
           
       Overseas
   
4,250
     
2,814
 
       In Israel
   
1,333
     
679
 
     
5,583
     
3,493
 
2)          Other:
               
        Payroll and related expenses
   
1,993
     
523
 
        Accrued expenses
   
707
     
372
 
    Accrual for vacation and recreation pay
   
431
     
310
 
        Other
   
-
     
538
 
     
3,131
     
1,743
 
Schedule of Cost of Revenues
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
License fees and royalties payable to licensor
   
3,027
     
3,024
     
230
 
Direct costs related to license revenues
   
203
     
2,605
     
-
 
Amortization of intangible asset
   
450
     
3,323
     
-
 
Cost of product sales
   
12
     
311
     
-
 
     
3,692
     
9,263
     
230
 
Schedule of Research and Development Expenses
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Research and development services
   
4,603
     
3,170
     
3,118
 
Payroll and related expenses
   
4,452
     
3,524
     
2,982
 
Lab, occupancy and telephone
   
969
     
1,102
     
855
 
Professional fees
   
935
     
273
     
390
 
Share-based compensation
   
760
     
451
     
104
 
Depreciation and amortization
   
583
     
431
     
495
 
Other
   
217
     
198
     
149
 
     
12,519
     
9,149
     
8,093
 
Schedule of Sales and Marketing Expenses
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Payroll and related expenses
   
8,868
     
12,224
     
-
 
Medical Affairs
   
4,824
     
2,891
     
-
 
Marketing
   
4,091
     
2,041
     
-
 
Travel
   
986
     
1,506
     
-
 
Office-related expenses
   
1,923
     
1,477
     
-
 
Business Analytics
   
1,005
     
1,264
     
-
 
Market Access
   
1,606
     
701
     
-
 
Professional fees
   
745
     
627
     
-
 
Share-based compensation
   
751
     
98
     
-
 
Depreciation and amortization
   
314
     
330
     
-
 
Loss on abandonment of right-of-use asset
   
-
     
246
     
-
 
Other
   
157
     
200
     
-
 
     
25,270
     
23,605
     
-
 
Schedule of General and Administrative Expenses
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Payroll and related expenses
   
2,117
     
2,000
     
1,407
 
Professional fees
   
2,028
     
1,991
     
1,290
 
Insurance
   
939
     
808
     
603
 
Share-based compensation
   
780
     
585
     
292
 
Depreciation
   
37
     
10
     
28
 
Provision for doubtful accounts receivable
   
-
     
800
     
(800
)
Other
   
409
     
127
     
324
 
     
6,310
     
6,321
     
3,144
 
Schedule of Non-Operating Income (Expenses), Net
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Changes in fair value of warrants
   
(11,054
)
   
18,965
     
8,599
 
Issuance costs
   
-
     
(669
)
   
(702
)
Other
   
235
     
139
     
180
 
     
(10,819
)
   
18,435
     
8,077
 
Schedule of Financial Income
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Interest income
   
2,007
     
1,820
     
1,124
 
Exchange differences, net
   
61
     
51
     
340
 
     
2,068
     
1,871
     
1,464
 
Schedule of Financial Expenses
   
Year ended December 31,
 
   
2023
   
2024
   
2025
 
   
in USD thousands
 
Interest expense
   
2,144
     
9,074
     
1,251
 
Bank commissions
   
25
     
45
     
29
 
     
2,169
     
9,119
     
1,280